TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
13.02
-0.10 (-0.76%)
At close: 4:00PM EDT

13.00 -0.02 (-0.15%)
Pre-Market: 7:11AM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close13.12
Open13.09
Bid13.08 x 2900
Ask13.04 x 4000
Day's Range12.70 - 13.10
52 Week Range6.07 - 13.76
Volume7,565,522
Avg. Volume17,349,160
Market Cap14.148B
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-3.77
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 27, 2017
1y Target Est11.53
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
-8% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report
    Business Wire

    Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report, demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content.

  • 3 Buffett Stocks That Are Trouncing Berkshire Hathaway So Far This Year
    Motley Fool

    3 Buffett Stocks That Are Trouncing Berkshire Hathaway So Far This Year

    Three Buffett stocks, in particular, are trouncing Berkshire in 2020. While the COVID-19 pandemic has hurt many companies, Amazon's business has thrived. The impact of the global novel coronavirus outbreak has turned Amazon's business upside down -- mostly in a good way.

  • Is Teva Pharmaceuticals Stock a Buy?
    Motley Fool

    Is Teva Pharmaceuticals Stock a Buy?

    Teva Pharmaceutical Industries (NYSE: TEVA) is a well known generic drugmaker that's attracted the attention of a number of well-known investors in the past. Most notably, Warren Buffett's Berkshire Hathaway bought shares of the company a number of years ago due, in no small part due to how cheap the stock was at the time. Teva's business can be split up into two main areas: its generics business and its own branded drug products.

  • Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?
    Zacks

    Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Benzinga

    Cramer Shares His Thoughts On Teva, Oxford Industries And More

    On CNBC's "Mad Money Lightning Round," Jim Cramer said he wouldn't buy Teva Pharmaceutical Industries Ltd (NYSE: TEVA). He explained that it's a generic drugmaker and those stocks are pretty awful in comparison to Merck & Co., Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE) and Bristol-Myers Squibb Co (NYSE: BMY).Instead of Oxford Industries Inc (NYSE: OXM), Cramer would rather buy PVH Corp (NYSE: PVH).Cramer likes Amgen, Inc. (NASDAQ: AMGN) and its new oncological franchise.He prefers Advanced Micro Devices, Inc. (NASDAQ: AMD) over Intel Corporation (NASDAQ: INTC). He believes AMD will take some market share from Intel with its new chips.Cramer said the CEO of General Electric Company (NYSE: GE) is doing a fantastic job against tremendous circumstances, but he doesn't see the investment in the stock as a diversification strategy.Cramer likes SpartanNash Co (NASDAQ: SPTN) a lot. He thinks that something must be going on and he sees the stock as a good one.He would sell a half of a position in Ingevity Corp (NYSE: NGVT) and let the rest run.See more from Benzinga * Cramer Weighs In On Beyond Meat, Canopy Growth, Penn National And More * Cramer Gives His Opinion On GW Pharma, Bed Bath & Beyond And More * Cramer Shares His Thoughts On Inovio, Raytheon And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Got $3,000? These 5 Beaten-Down Stocks Are Begging to Be Bought
    Motley Fool

    Got $3,000? These 5 Beaten-Down Stocks Are Begging to Be Bought

    No matter how dire things may have appeared in previous bear markets, bull-market rallies eventually erase all evidence of downward moves in the stock market. Also keep in mind that you don't have to be rich to generate a handsome return from the stock market. With the exception of the oil and gas industry, there's probably not a harder-hit industry lately than bank stocks.

  • Teva Announces Virtual 2020 Annual Meeting of Shareholders
    Business Wire

    Teva Announces Virtual 2020 Annual Meeting of Shareholders

    Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) ("Teva"), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva’s 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.m., New York time), as previously announced.

  • Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine
    Business Wire

    Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic.

  • Can Teva (TEVA) Return to Growth in This Year or Next?
    Zacks

    Can Teva (TEVA) Return to Growth in This Year or Next?

    Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.

  • Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injection) at European Academy of Neurology Congress
    Business Wire

    Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injection) at European Academy of Neurology Congress

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on AJOVY® (fremanezumab) and the burden of migraine in Europe will be presented at the 6th Congress of the European Academy of Neurology (EAN), being held virtually from 23-26 May 2020. Additionally, Teva will present data on the long-term safety and efficacy of COPAXONE® (glatiramer acetate injection). This year’s EAN congress is a virtual meeting due to the global coronavirus pandemic. All Teva abstracts will be published in a supplement to the European Journal of Neurology.

  • Teva Pharmaceutical Could Be Making a Comeback
    TheStreet.com

    Teva Pharmaceutical Could Be Making a Comeback

    The charts of Teva Pharmaceutical Industries, Inc. have been in a five-year decline but it looks like aggressive buying is making a return to this name. In the daily bar chart of TEVA, below, we can see that buyers have shown up in the $7-$6 area in August, September and October and again this March. The On-Balance-Volume (OBV) line has been rising for much of the past 12 months and suggests we are seeing some significant accumulation.

  • 3 Absolutely No-Brainer Bear Market Buys
    Motley Fool

    3 Absolutely No-Brainer Bear Market Buys

    Beginning in late February, we witnessed the broad-based S&P 500 endure the fastest descent into bear market territory in history -- it took a little over three weeks. Every bear market correction in history has proved to be an excellent buying opportunity for long-term-minded investors. This means that if you buy businesses with game-changing potential at a discount during a bear market, you'll be setting yourself up to make a lot of money.

  • Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'
    Yahoo Finance Video

    Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'

    Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja joins Yahoo Finance’s Seana Smith to discuss President Trump’s remarks that he is taking hydroxychloroquine as a preventative measure against COVID-19.

  • China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults
    Business Wire

    China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the China National Medical Products Administration (NMPA) has approved AUSTEDO® (Deutetrabenazine Tablets) for the treatment of chorea associated with Huntington's disease (HD) and Tardive Dyskinesia (TD) in adults, after a priority review. China is the second country in the world after the U.S. to have approved AUSTEDO.

  • Coronavirus update: New outbreaks reported in states that plan to reopen soon, while Trump suggests testing is ‘overrated’
    MarketWatch

    Coronavirus update: New outbreaks reported in states that plan to reopen soon, while Trump suggests testing is ‘overrated’

    The U.S. death toll from the coronavirus that causes COVID-19 rose above 87,000 on Saturday, as new outbreaks were reported from states where stay-at-home orders are set to expire and in states that never imposed them, raising concerns that the reopening of economies will spur new infections.

  • MarketWatch

    Government trial to test hydroxychloroquine, antibiotic combo in COVID-19 patients

    The National Institute of Allergy and Infectious Diseases (NIAID) said it launched a clinical trial testing hydroxychloroquine and azithromycin in 2,000 patients with mild and moderate cases of COVID-19. Hydroxychloroquine is approved by the Food and Drug Administration (FDA) to treat malaria, lupus, and rheumatoid arthritis; azithromycin is a commonly prescribed antibiotic. The trial was announced during Dr. Rick Bright's testimony before a House of Representatives committee on Thursday. Bright has filed a whistleblower lawsuit alleging that his reluctance to promote hydroxychloroquine as a treatment for COVID-19 led to his demotion within the National Institutes of Health. Teva Pharmaceutical Industries Ltd. donated the hydroxychloroquine for the trial, which is evaluating whether the drug combination can prevent hospitalization and death. "Although there is anecdotal evidence that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes," NIAID director Dr. Anthony Fauci said in a statement. The FDA in March granted an emergency use authorization to hydroxychloroquine and chloroquine as COVID-19 treatments. More recently, the regulator authorized Gilead Sciences Inc.'s remdesivir as a COVID-19 treatment; however, there are no proven, FDA-approved therapies that treat the disease caused by the novel coronavirus. There are dozens of other clinical trials underway evaluating hydroxychloroquine in COVID-19 patients.

  • Barrons.com

    13 Stock Ideas From Top Value Managers

    Veteran value managers gathered by Ariel Investments earlier this week for a virtual discussion said they have been snapping up a wide-range of stocks during the coronavirus-induced volatility.

  • Is Teva Pharmaceutical Industries Ltd (TEVA) Stock Undervalued Right Now?
    Zacks

    Is Teva Pharmaceutical Industries Ltd (TEVA) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Teva Pharmaceutical Industries Limited (TEVA) Q1 2020 Earnings Call Transcript
    Motley Fool

    Teva Pharmaceutical Industries Limited (TEVA) Q1 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to today's Teva Pharmaceutical First Quarter 2020 Financial Results. Delay, I would now like to hand the conference over to presenter today, Kevin Mannix, Senior Vice President and Head of Investor Relations. Thank you, operator, and thank you, everyone, for joining us today to discuss Teva's First Quarter 2020 Financial Results.

  • Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales
    Zacks

    Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales

    Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.

  • Teva Pharmaceutical's Q1 Earnings Beat Helps RS Rating Jump To 90
    Investor's Business Daily

    Teva Pharmaceutical's Q1 Earnings Beat Helps RS Rating Jump To 90

    One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Teva Pharmaceutical cleared that benchmark Thursday, with a jump from 80 to 90 Thursday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

  • GuruFocus.com

    2 Stocks With High Potential on Thursday

    Shares of JetBlue Airways and Teva Pharmaceuticals jump strong on earnings Continue reading...

  • Generic-Drug Powerhouse Jumps On 'Strong Beat,' Reaffirmed Outlook
    Investor's Business Daily

    Generic-Drug Powerhouse Jumps On 'Strong Beat,' Reaffirmed Outlook

    Teva Pharmaceutical beat Wall Street's first-quarter expectations Thursday, leading Teva stock to rocket to a three-month high. Teva also reaffirmed its revenue guidance for the year.

  • Teva CEO Kare Schultz On Drugmaker's Outlook, Coronavirus Response
    Benzinga

    Teva CEO Kare Schultz On Drugmaker's Outlook, Coronavirus Response

    Generic drugmaker Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported a first-quarter earnings beat as the company managed to maintain business continuity, CEO Kare Schultz said on CNBC's "Squawk on the Street."Teva's 'Very Good' Quarter Teva is dedicated to supplying therapies to the 200 million people who use its generic drugs and this resulted in a "very good" quarter, the CEO said.Looking forward, the company expects to see "some reversal" of the strong demand seen in March, but Schultz said full-year revenue should fall within its guidance.Teva Supply Chain Update One of Teva's drugs, propofol, experienced shipping delays due to the COVID-19 pandemic. Part of the problem stems from a reduction in air traffic, less air cargo availability and some countries placing new restrictions on imported goods.While air cargo issues remain a problem, Teva is seeing improving conditions, as it has been able to increase volume outputs, but with higher transportation costs.In the meantime, all of Teva's facilities are operating at "full capacity," Schultz said, and the "majority" of logistical problems have been overcome.Teva And The Hydroxychloroquine Controversy Teva is one of the few makers of the anti-malaria drug hydroxychloroquine, which has come under its fair share of controversy.The CEO said he can't at this time offer a "clarifying answer" on the efficacy of the drug in treating COVID-19. The ultimate responsibility rests with the health care professionals, he said.View more earnings on TEVANevertheless, Teva was able to respond to the growing demand for the drug and was "quite successful" in shipping the product, Schultz said. Teva CEO On Coronavirus Second Wave Concerns The coronavirus could return for a "second wave" in the fall season, but it is "too early to say" what, if any, actions hospitals are taking now to prepare themselves, Schultz said.It is nevertheless important for all companies to increase the production of products to better prepare in the event of a second wave outbreak, he said. Teva shares were up 10.11% at $11.54 at the time of publication Thursday.Related Links:Chloroquine, Hydroxychloroquine And Coronavirus: What You Should KnowSanofi CEO Talks Coronavirus Vaccine Development, Potential TreatmentSee more from Benzinga * Papa John's CEO Says Chain Had Best Month Ever Due To More Than Just Coronavirus Trends * Coronavirus Drives Surge In Online Grocery Penetration For Players Like Amazon Prime Now, Walmart * These Analysts Aren't Supporting Beyond Meat's Stock Surge(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.